ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

CORRECT(12/13): FDA Panel Recommends Use Of Alexza Pharma's Bipolar Treatment

("FDA Panel Recommends Use Of Alexza Pharma's Bipolar Treatment" on Dec. 13 and an earlier story on Jan. 18 misstated that Valeant Pharmaceuticals International Inc. is currently a commercial partner for the drug. A corrected version follows:) DOW JONES NEWSWIRES Alexza Pharmaceuticals Inc. (ALXA) said a U.S. Food and Drug Administration panel has recommended that its schizophrenic and bipolar disorder treatment be approved for use. Shares were recently up 76% to $1.10 as the company's chief executive called the panel's recommendation "another step forward" for the drug's development. Alexza in August said it refiled its new drug application for the treatment, adding new data and sections that aimed to address safety concerns raised by the agency last year. "If approved, we believe Adasuve represents a valuable treatment option for patients and physicians alike. We look forward to continuing to work toward our goal of bringing Adasuve to market in 2012," said Chief Executive Thomas B. King. Alexza last month reported its third-quarter loss widened sharply from a year earlier as it recorded higher research and development expenses and a loss on a contingent liability. -By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
09/16/201409:44:34U.S. Hot Stocks: Hot Stocks to Watch
09/12/201415:14:59Correction to Allergan Story
08/14/201418:03:34Paulson & Co. Opens Positions in Covidien, DirecTV and Allergan
07/21/201415:44:16Allergan to Lay Off 13% of Workforce, Cut Drug Research -- 3rd...
07/21/201409:59:43U.S. Hot Stock Futures: Hot Stocks to Watch
07/21/201407:57:43Valeant Pharmaceuticals Complains to SEC Over Allergan Claims...
07/07/201414:00:26Pershing Proposes Six Directors for Allergan Board
07/02/201415:32:44Pershing Square Hedge Fund Ends First Half Up 25%
07/01/201414:39:11Pershing Square Hires Credit Suisse as Banker in Allergan Campaign...
06/17/201409:09:22Valeant to Launch Exchange Offer This Week to Allergan Shareholders...
06/16/201421:23:19Allergan's Bitter Pill for Morgan Stanley
06/13/201408:08:46Pershing Files Suit Against Allergan -- 2nd Update
06/13/201407:19:22Pershing Capital Files Suit Against Allergan -- Update
06/10/201416:41:13Allergan Rejects Valeant's Latest Takeover Bid -- 4th Update
06/10/201416:36:52Allergan Rejects Valeant's Latest Takeover Bid -- 3rd Update
06/10/201416:29:53Allergan Rejects Valeant's Latest Takeover Bid -- Update
06/02/201416:54:18MARKET SNAPSHOT: U.S. Stocks Inch Up; S&P 500, Dow At Record
06/02/201413:25:07MARKET SNAPSHOT: U.S. Stocks Regain Footing After ISM Corrects...
06/02/201411:41:10Pershing Seeks Removal of 6 Allergan Directors -- 4th Update
06/02/201411:30:24MARKET SNAPSHOT: U.S. Stocks Turn Lower On Weak Manufacturing...

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad